TCGA-CV-5431-01A-01R-1514-07
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
- overall_survival_months
- 0.119178082
- sex
- male
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- ALLOGRAFT_REJECTION+0.500
- TNFA_SIGNALING_VIA_NFKB+0.440
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.390
- IL6_JAK_STAT3_SIGNALING+0.370
- ANGIOGENESIS+0.360
- INFLAMMATORY_RESPONSE+0.340
- MYC_TARGETS_V2+0.330
- APICAL_SURFACE+0.260
- KRAS_SIGNALING_UP+0.250
- IL2_STAT5_SIGNALING+0.220
Top 10 suppressed
- INTERFERON_ALPHA_RESPONSE-0.350
- OXIDATIVE_PHOSPHORYLATION-0.350
- PROTEIN_SECRETION-0.340
- FATTY_ACID_METABOLISM-0.330
- XENOBIOTIC_METABOLISM-0.310
- ADIPOGENESIS-0.290
- PEROXISOME-0.260
- MYOGENESIS-0.240
- P53_PATHWAY-0.210
- BILE_ACID_METABOLISM-0.180
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | C3N-02192 | — | cohortMD2 | 0.760 |
| 2 | DRR168603 | — | — | 0.729 |
| 3 | SRR934781 | — | — | 0.723 |
| 4 | ERR2278875 | — | — | 0.721 |
| 5 | 4170ae68-a4d2-4095-af47-4f981f7812a4 | — | — | 0.719 |
| 6 | SRR25043625 | — | — | 0.719 |
| 7 | TCGA-S3-AA15-01A-11R-A41B-07 | — | D | 0.712 |
| 8 | SRR1313158 | — | D | 0.712 |
| 9 | ebff0d05-b930-42b7-a428-694cef63ebb5 | — | — | 0.705 |
| 10 | SRR6013589 | — | cohortSQ1 | 0.701 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 22 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.440 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.390 | Inavolisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.370 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.360 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| MYC_TARGETS_V2 | 0.330 | Idelalisib | — uncovered |
| APICAL_SURFACE | 0.260 | Temsirolimus | — uncovered |
| KRAS_SIGNALING_UP | 0.250 | Inavolisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.220 | Idelalisib | — uncovered |
| UV_RESPONSE_DN | 0.210 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.210 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.190 | Inavolisib | — uncovered |
| HYPOXIA | 0.160 | Idelalisib | — uncovered |
| COAGULATION | 0.150 | Binimetinib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.120 | Idelalisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.080 | Remibrutinib | — uncovered |
| E2F_TARGETS | 0.080 | Inavolisib | — uncovered |
| COMPLEMENT | 0.070 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.050 | Inavolisib | — uncovered |